-+ 0.00%
-+ 0.00%
-+ 0.00%

On September 16, Johnson & Johnson announced that Recojet® — Eventumab injection was officially launched in China. Unilico® is suitable for first-line treatment of adult patients with locally advanced or metastatic advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 or exon 21 L858R replacement mutations.

Zhitongcaijing·09/16/2026 11:57:11
Listen to the news
On September 16, Johnson & Johnson announced that Recojet® — Eventumab injection was officially launched in China. Unilico® is suitable for first-line treatment of adult patients with locally advanced or metastatic advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 or exon 21 L858R replacement mutations.